Literature DB >> 35675094

From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.

Rita Rubin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35675094     DOI: 10.1001/jama.2022.9925

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022.

Authors:  Lindsey Wang; Nathan A Berger; Pamela B Davis; David C Kaelber; Nora D Volkow; Rong Xu
Journal:  medRxiv       Date:  2022-06-22

Review 2.  Viral Nucleases from Herpesviruses and Coronavirus in Recombination and Proofreading: Potential Targets for Antiviral Drug Discovery.

Authors:  Lee R Wright; Dennis L Wright; Sandra K Weller
Journal:  Viruses       Date:  2022-07-16       Impact factor: 5.818

3.  Safety, Efficacy and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected with SARS-CoV-2.

Authors:  Arnaud Devresse; Sébastien Briol; Julien De Greef; Florian Lemaitre; Lidvine Boland; Vincent Haufroid; Anais Scohy; Benoit Kabamba; Jean Cyr Yombi; Leila Belkhir; Tom Darius; Antoine Buemi; Kristell De Potter; Rebecca Mantegazza; Bertrand Bearzatto; Eric Goffin; Nada Kanaan
Journal:  Kidney Int Rep       Date:  2022-08-28

4.  Real-world effectiveness of oral antivirals for COVID-19.

Authors:  Charles Burdet; Florence Ader
Journal:  Lancet       Date:  2022-10-08       Impact factor: 202.731

Review 5.  Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild-moderate COVID-19 and prevention of post-COVID cognitive impairment.

Authors:  Adel A Gomaa; Yasmin A Abdel-Wadood; Mohamed A Gomaa
Journal:  Inflammopharmacology       Date:  2022-09-22       Impact factor: 5.093

6.  The compartmentalized upper respiratory mucosa needs time to rally a sufficient immune force for SARS-CoV-2 clearance.

Authors:  Xiaowen Zheng; Xiaoping Tang; Feng Li
Journal:  Cell Mol Immunol       Date:  2022-10-11       Impact factor: 22.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.